Skip Navigation
Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Monday, April 26, 2004

Media Contact:
Anne A. Oplinger
(301) 402-1663
niaidnews@niaid.nih.gov
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

HIV Patients Get Long-Term Boost with Short, Intermittent Drug Regimen

National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 (IL-2) allow people with HIV to maintain near normal levels of a key immune system cell for long periods. The researchers, from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and the Warren G. Magnuson Clinical Center, describe their findings in the May 1 issue of the journal Blood.

For information about AIDS treatment or to enroll in a clinical study, please contact www.AIDSinfo.nih.gov
or call: 1-800-HIV-0440
(1-800-448-0440).

"These data provide strong evidence that IL-2 therapy, which can be self-administered by patients, could be an important adjunct to highly active antiretroviral therapy (HAART)," says NIAID Deputy Director John R. La Montagne, Ph.D.

The new report summarizes the experience of 77 HIV-positive individuals who enrolled in extension phases of three long-running AIDS clinical trials. Participants were taught to inject themselves subcutaneously with IL-2 twice daily in 5-day-long cycles. Cycles were initiated as often as necessary to maintain levels of immune cells called CD4+ T cells at predetermined, individually tailored amounts. HIV infection causes progressive loss of CD4+ T cells. Without enough of these "helper" immune cells, people with HIV disease have a hard time fending off infections. IL-2 can boost CD4+ T cell levels, with the goal of improving overall immune health.

Because HIV infection causes progressive immune destruction, it stands to reason that immune-stimulation therapy, such as IL-2, might play a substantial role in treating patients with this condition, notes Richard Davey, Jr., M.D., an NIAID AIDS clinician who headed the studies reported in Blood. Indeed, during the early 1980s NIH physicians pioneered the use of long courses of IL-2 to treat individuals whose immune systems had mysteriously failed. Scientists now know those people were suffering from AIDS, but at the time the virus causing AIDS had yet to be identified.

Although NIH physicians have accumulated over 20 years of experience with IL-2 therapy, the most impressive results began to appear in the early 1990s when the doctors started treating patients with short, intermittent cycles of the drug, Dr. Davey says. Today, HIV patients receiving IL-2 therapy typically begin with 5-day-long cycles every other month while taking drugs, such as HAART, on a sustained basis. According to Dr. Davey, this regimen often raises an HIV patient's CD4+ T cell levels well into the normal range after only a few cycles. The new research suggests IL-2 therapy can then be administered much less frequently without loss of benefit.

Most studies to date have looked at IL-2 therapy only over relatively short periods, says Dr. Davey. In contrast, the average length of patient follow-up described in the current paper is about six years. Patients in these trials have received an average of 10 IL-2 cycles during the course of their involvement, with most of the cycles occurring in the initial years of participation. Of the original 77 volunteers, 61 achieved and maintained normal or nearly normal levels of CD4+ T cells for periods ranging from two to 91 months between IL-2 cycles. During the most recent period of study, the average time between cycles was more than 3 years. (Of the 16 people no longer participating, one died, one developed non-Hodgkin's lymphoma, eight elected to follow other treatment plans and six experienced CD4 cell count declines that did not respond to IL-2 therapy.)

"Patients described in this study are still being followed," says Dr. Davey. "There are also trials planned or underway to learn if IL-2 therapy could delay or obviate the need for continuous HAART, thereby sparing persons with HIV disease from the serious side-effects that HAART can cause. The early experience from some small preliminary studies in this area suggests that this may indeed be a possibility, although larger trials are clearly needed to explore this fully."

###

###

References:

CE Farel et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 103:3282-86. Published online January 15, 2004.DOI: 10.1182/blood-2003-09-3283.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​​​

Last Updated April 26, 2004